JP2019043956A5 - - Google Patents

Download PDF

Info

Publication number
JP2019043956A5
JP2019043956A5 JP2018210546A JP2018210546A JP2019043956A5 JP 2019043956 A5 JP2019043956 A5 JP 2019043956A5 JP 2018210546 A JP2018210546 A JP 2018210546A JP 2018210546 A JP2018210546 A JP 2018210546A JP 2019043956 A5 JP2019043956 A5 JP 2019043956A5
Authority
JP
Japan
Prior art keywords
composition
ile
leu
bdnf
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018210546A
Other languages
Japanese (ja)
Other versions
JP2019043956A (en
JP7108521B2 (en
Filing date
Publication date
Application filed filed Critical
Publication of JP2019043956A publication Critical patent/JP2019043956A/en
Publication of JP2019043956A5 publication Critical patent/JP2019043956A5/ja
Application granted granted Critical
Publication of JP7108521B2 publication Critical patent/JP7108521B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (4)

ホエイタンパク質加水分解物を有効成分とする体内の脳由来神経栄養因子(BDNF)量増加促進用組成物であって、当該ホエイタンパク質加水分解物がIle−Leu、Leu−Leu、Val−Leu、Ile−Val、Ile−Ile、Leu−Val、及びLeu−Ileのジペプチドを含有するものであり、
非運動状態のヒトを含む哺乳動物(運動前または運動中のヒトを含む哺乳動物を除く)に経口投与または摂取されるものである、BDNF量増加促進用組成物。
A composition for promoting an increase in the amount of brain-derived neurotrophic factor (BDNF) in the body containing a whey protein hydrolyzate as an active ingredient, and the whey protein hydrolyzate is Ile-Leu, Leu-Leu , Val-Le. u, Ile-Val, Ile- Ile, der those containing dipeptides Leu-Val, and Leu-Ile is,
Ru der those in the non-motion state in a mammal, including a human (except for mammals, including humans during exercise before or motion) are administered orally or ingested, BDNF amount increase for promoting composition.
認知機能低下者、またはその予備群に経口投与または摂取されるものである、請求項1に記載するBDNF量増加促進用組成物。 The composition for promoting an increase in the amount of BDNF according to claim 1, which is orally administered or ingested to a cognitively impaired person or a reserve group thereof. 認知機能の低下抑制または改善用組成物である、請求項に記載するBDNF量増加促進用組成物。 The composition for promoting an increase in the amount of BDNF according to claim 2 , which is a composition for suppressing or improving a decrease in cognitive function. 飲食物である、請求項1〜のいずれか1項に記載するBDNF量増加促進用組成物。 A food, BDNF amount increase promotion composition according to any one of claims 1-3.
JP2018210546A 2017-03-10 2018-11-08 Composition for promoting an increase in the amount of BDNF in the body Active JP7108521B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017046378 2017-03-10
JP2017046378 2017-03-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018530630A Division JP6435079B1 (en) 2017-03-10 2018-03-09 Composition for promoting an increase in the amount of BDNF in the body

Publications (3)

Publication Number Publication Date
JP2019043956A JP2019043956A (en) 2019-03-22
JP2019043956A5 true JP2019043956A5 (en) 2021-04-22
JP7108521B2 JP7108521B2 (en) 2022-07-28

Family

ID=63448663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530630A Active JP6435079B1 (en) 2017-03-10 2018-03-09 Composition for promoting an increase in the amount of BDNF in the body
JP2018210546A Active JP7108521B2 (en) 2017-03-10 2018-11-08 Composition for promoting an increase in the amount of BDNF in the body

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018530630A Active JP6435079B1 (en) 2017-03-10 2018-03-09 Composition for promoting an increase in the amount of BDNF in the body

Country Status (4)

Country Link
JP (2) JP6435079B1 (en)
CN (1) CN110381965A (en)
TW (1) TWI773739B (en)
WO (1) WO2018164254A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7011984B2 (en) * 2018-07-13 2022-01-27 キリンホールディングス株式会社 Composition for improving attention function and judgment function
JP2020058346A (en) * 2018-10-05 2020-04-16 公立大学法人名古屋市立大学 Composition for improving cognitive function
JP2020176100A (en) * 2019-04-22 2020-10-29 株式会社明治 Compositions for suppressing exercise-induced muscle damage
WO2020239998A1 (en) * 2019-05-29 2020-12-03 Arla Foods Amba Palatable extensively hydrolysed whey protein hydrolysates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2039366A4 (en) * 2006-04-21 2010-01-06 Meiji Seika Kaisha Composition containing peptide as the active ingredient
MX2016007630A (en) * 2013-12-13 2016-09-09 Nestec Sa Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions.
BR112016027871A2 (en) * 2014-06-16 2017-10-24 Kirin Kk composition to improve memory, learning function and / or cognitive function
JPWO2017026429A1 (en) * 2015-08-10 2018-05-31 株式会社明治 Muscle synthesis promoter

Similar Documents

Publication Publication Date Title
JP2019043956A5 (en)
Budhiraja et al. Sleep-disordered breathing and cardiovascular disorders
JP2018193377A5 (en)
JP2018012722A5 (en)
JP2014530874A5 (en)
JP2017222722A5 (en)
JP2014198723A5 (en)
Wood The mechanism of the increased venous pressure with exercise in congestive heart failure
Jakovljevic et al. The effect of aerobic versus resistance exercise training on peak cardiac power output and physical functional capacity in patients with chronic heart failure
Emerson Artificial respiration in the treatment of edema of the lungs: A suggestion based on animal experimentation
RU2013134133A (en) APPLICATION OF LACTOFERRINE-CONTAINING NUTRITIONAL COMPOSITIONS IN MAINTAINING RESISTANCE TO DISEASES AND CONDITIONS
ATE493974T1 (en) ORAL TEDISAMIL FORMULATIONS HAVING GASTRIC RETENTION AND SUSTAINED RELEASE PROPERTIES
FI3484475T3 (en) 1-methylnicotinamide for the treatment of cardiovascular disease
Nose et al. Interactions between body fluid homeostasis and thermoregulation in humans
JP2018199643A5 (en)
JP2019156793A5 (en)
Agin et al. Effects of whey protein and resistance exercise on body composition and muscle strength in women with HIV infection
JP2020137724A5 (en)
Turkova et al. Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial
JP2015509934A5 (en)
JP2017502089A5 (en)
JP2006504741A5 (en)
Kara et al. Reversible sensorineural hearing loss in a girl with Kawasaki disease.
JP2020137722A5 (en)
MA49790A (en) DIETARY SUPPLEMENT, IN THE FORM OF A SINGLE-DOSE ORAL SOLUTION CONSISTING OF MAGNESIUM, MELATONIN, TRYPTOPHAN AND 5-HYDROXYTRYPTOPHANE, USEFUL TO REDUCE SLEEP TIME